celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
![Celcuity logo](https://files.capedge.com/8-K/0001144204-18-043302/image_001.jpg)
Company profile
Ticker
CELC
Exchange
Website
CEO
Brian F. Sullivan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Quest Diagnostics • Labcorp • Fortrea • Radnet • Akumin • Burning Rock Biotech • Guardant Health • Exact Sciences • Genomic Health • Invitae ...
Former names
Celcuity LLC
SEC CIK
CELC stock data
Latest filings (excl ownership)
D/A
$184.50 mm in debt / options / securities to be acquired, sold $100.00 mm, 2 investors
28 Jun 24
8-K
Celcuity Announces Pricing of Underwritten Common Stock Offering
31 May 24
424B5
Prospectus supplement for primary offering
30 May 24
8-K
Entry into a Material Definitive Agreement
30 May 24
S-8
Registration of securities for employees
20 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
15 May 24
8-K
Departure of Directors or Certain Officers
13 May 24
D/A
$75.38 mm in debt / options / securities to be acquired, sold $35.00 mm, 1 investor
25 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Mar 24
Transcripts
CELC
Earnings call transcript
2024 Q1
15 May 24
CELC
Earnings call transcript
2023 Q4
27 Mar 24
CELC
Earnings call transcript
2023 Q3
13 Nov 23
CELC
Earnings call transcript
2023 Q2
10 Aug 23
CELC
Earnings call transcript
2023 Q2
10 Aug 23
CELC
Earnings call transcript
2023 Q1
15 May 23
CELC
Earnings call transcript
2022 Q4
23 Mar 23
CELC
Earnings call transcript
2022 Q3
13 Nov 22
CELC
Earnings call transcript
2022 Q2
13 Aug 22
CELC
Earnings call transcript
2022 Q1
17 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.21 mm | 31.21 mm | 31.21 mm | 31.21 mm | 31.21 mm | 31.21 mm |
Cash burn (monthly) | (no burn) | 202.04 k | 7.50 mm | 6.35 mm | 5.69 mm | 4.83 mm |
Cash used (since last report) | n/a | 781.08 k | 28.99 mm | 24.54 mm | 22.00 mm | 18.69 mm |
Cash remaining | n/a | 30.43 mm | 2.23 mm | 6.67 mm | 9.22 mm | 12.53 mm |
Runway (months of cash) | n/a | 150.6 | 0.3 | 1.1 | 1.6 | 2.6 |
Institutional ownership, Q1 2024
18.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 13 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 2.92 bn |
Total shares | 6.48 mm |
Total puts | 0.00 |
Total calls | 9.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Soleus Capital Master Fund | 2.29 mm | $0.00 |
Venrock Healthcare Capital Partners II | 2.17 mm | $0.00 |
Growth Equity Opportunities 18 VGE | 1.52 mm | $15.20 mm |
Gagnon Neil | 342.83 k | $8.35 mm |
BK Bank Of New York Mellon | 46.45 k | $1.00 bn |
JNBA Financial Advisors | 38.09 k | $822.77 mm |
Wealth Enhancement Advisory Services | 20.43 k | $441.29 mm |
Trust Point | 19.40 k | $418.93 mm |
Commonwealth Equity Services | 15.12 k | $327.00 k |
BNP Paribas Arbitrage | 8.94 k | $193.04 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jun 24 | Buller Richard E | Common Stock | Sell | Dispose S | Yes | Yes | 15.68 | 350 | 5.49 k | 7,381 |
10 Jun 24 | Nigon Richard | Common Stock | Acquire X | No | No | 9.5 | 5,061 | 48.08 k | 101,093 | |
10 Jun 24 | Nigon Richard | Warrants Common Stock | Dispose X | No | No | 9.5 | 5,061 | 48.08 k | 0 | |
4 Jun 24 | Nigon Richard | Stock Option Common Stock | Grant | Acquire A | No | No | 14.83 | 8,153 | 120.91 k | 8,153 |
4 Jun 24 | Polly A. Murphy | Stock Option Common Stock | Grant | Acquire A | No | No | 14.83 | 8,153 | 120.91 k | 8,153 |
4 Jun 24 | Furcht Leo | Stock Option Common Stock | Grant | Acquire A | No | No | 14.83 | 8,153 | 120.91 k | 8,153 |
News
Leerink Partners Initiates Coverage On Celcuity with Outperform Rating, Announces Price Target of $29
22 Jul 24
Needham Maintains Buy on Celcuity, Lowers Price Target to $23
31 May 24
Celcuity Plans To Initiate Phase 3 Clinical Trial To Evaluate Gedatolisib Plus CDK4/6 Inhibitor And Fulvestrant; Enters Amendment To Existing Debt Facility Agreement
30 May 24
Stifel Maintains Buy on Celcuity, Maintains $40 Price Target
16 May 24
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $27 Price Target
16 May 24
Press releases
Celcuity To Participate in Jefferies Global Healthcare Conference
3 Jun 24
Celcuity Announces Pricing of Underwritten Common Stock Offering
30 May 24
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
30 May 24
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
15 May 24
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
8 May 24